Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow

Julie A. Vincent, Robert D. Ross, Joseph Kassab, Julie M. Hsu, William W. Pinsky

Research output: Contribution to journalArticlepeer-review

75 Scopus citations


Endothelin-1 (ET), a potent vasoconstrictor peptide, has been found to be elevated in children with pulmonary hypertension associated with congenital heart defects. To evaluate the effect of pulmonary blood flow on ET concentrations, 5 ml blood samples were obtained peripherally at cardiac catheterization from 35 patients, ages 0.13 to 17 years (median 2). Plasma was extracted and ET measured by radioimmunoassay. Patients were classified into 2 groups based on the presence (group A) or absence (group B) of increased pulmonary blood flow defined as a Qp Qs ≥1.5. When the 13 patients (37%) in group A were compared with the 22 patients (63%) in group B there were no significant differences in age, cardiac index, or pulmonary and systemic resistances. ET concentrations were significantly higher in group A patients (median 3.25, range 0 to 16.5 vs median 0, range 0 to 6.35 pg/ml; p ≤ 0.05). Pulmonary Mood flow and pulmonary artery pressure were also higher in group A patients (p ≤ 0.01). When patients within group A were subdivided into those with and without pulmonary hypertension, no difference was present in their ET concentrations (mean/SD: 4.4 4.3 vs 4.0 6.4 pg/ml, p = NS). Thus, ET is elevated in patients with congenital heart disease associated with left-to-right shunts and it appears that this increase is related to increased pulmonary blood flow independent of pulmonary artery pressure.

Original languageEnglish
Pages (from-to)1204-1207
Number of pages4
JournalThe American Journal of Cardiology
Issue number13
StatePublished - May 15 1993


Dive into the research topics of 'Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow'. Together they form a unique fingerprint.

Cite this